OKYO Stock Forecast & Price Target

OKYO Pharma Ltd has shown significant progress in the clinical development of its therapeutic, urcosimod, aimed at treating inflammatory eye diseases and chronic pain. Notably, 67% of patients receiving the 0.05% urcosimod formulation demonstrated more than a 50% improvement in pain compared to 33% in the placebo group, highlighting its efficacy. Additionally, marked reductions in pain scores were observed as early as Week 4, further supporting a positive outlook for the company's advancements in biopharmaceutical solutions.

OKYO Pharma Ltd reported a significant net loss of $4.7 million, or $0.12 per share, for the fiscal year ending March 31, 2025, indicating financial instability. The company's therapeutic candidate, urcosimod, demonstrates concerning efficacy metrics, as all patients in the treatment group exhibited moderate to severe pain levels, while a majority in the placebo group presented with only mild pain, raising doubts about its clinical viability. Additionally, the company faces multiple risks, including potential clinical trial failures, challenges securing regulatory approval in the U.S., and threats from competition and market penetration, contributing to a pessimistic outlook for future performance.